Vaxcyte, Inc. PCVX
We are a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. 10-K, Item 1
- Headquarters
- San Carlos, CA
- CEO
- Grant Pickering
- Next results
- around Feb 23, 2027
What changed
19 new risk paragraphs. 10-K filed Feb 24, 2026 against Feb 25, 2025.
Each row opens the detail with the quote and the filing. A row is a change worth reading, not a verdict.
Accounting checks
9 checks on the latest 10-K. Checks, not verdicts.
0facts worth reading about all 9 checks found nothing to note
-
Cash from operations −$655.6M vs net income −$766.6M (FY ending Dec 31, 2025)
-
Same auditor in both 10-Ks: Deloitte & Touche LLP
-
No statement of substantial doubt about going concern
6 more checks with nothing to note
-
No 8-K item 4.02 in the last 2 years
-
No NT 10-K or NT 10-Q in the last 2 years
-
The same matters as last year: Accrued Contract Manufacturing Expenses; Table of Contents
-
No sentence in the 10-K concludes that controls were not effective because of a material weakness
-
No 8-K item 2.06 in the last 2 years
-
No 8-K item 1.03 in the last 2 years
In their words
19 paragraphs in Risk Factors that were not in the 10-K filed Feb 25, 2025. Quoted as filed.
-
Item 1A · new paragraph · not in the 10-K filed Feb 25, 2025 10-K, ITEM 1A
New pediatric vaccines that receive an ACIP preferred recommendation are almost universally adopted, and adult vaccines that receive a preferred recommendation are widely adopted. Recent changes to federal vaccine policy have introduced new uncertainties regarding the regulatory, legal, and reimbursement landscape for vaccines in the…
-
Item 1A · new paragraph · not in the 10-K filed Feb 25, 2025 10-K, ITEM 1A
The success of our business depends in large part upon our ability to identify, develop and commercialize products based on our cell-free protein synthesis platform. In addition to our PCV franchise, our pipeline includes preclinical vaccine
-
Item 1A · new paragraph · not in the 10-K filed Feb 25, 2025 10-K, ITEM 1A
For example, we announced in August 2025 that preclinical data for VAX-PG demonstrated an acceptable safety profile but not sufficient efficacy signals to support further investment, and we therefore discontinued further development of that
-
Item 1A · new paragraph · not in the 10-K filed Feb 25, 2025 10-K, ITEM 1A
For example, our agreements with Lonza are denominated in Swiss Franc (“CHF”). Fluctuations in the exchange rate for CHF may increase our costs and affect our operating results.
New risk paragraphs, against peers
Latest 10-K of each, Health care companies closest in revenue
Paragraphs in Risk Factors with nothing like them in the company's 10-K the year before. A count of text, not of risk.
Recent filings
6 filings in the last 30 days · SEC EDGAR
-
SEC letterNov 14, 2026SEC asked 1 question about Form 10-K for the fiscal year ended December 31, 2024 letters Apr 10, 2025 to May 14, 2025
-
Planned saleNov 12, 2026Dhaliwal Harpreet S. (Officer) gave notice of a planned sale of 17,000 shares worth about $1.2M Form 144, approximate sale date Nov 11, 2026, under a 10b5-1 plan adopted Apr 6, 2026
-
8-KNov 4, 2026Quarterly results 8-K item 2.02
-
10-QNov 4, 2026Quarterly report (10-Q) period ended Sep 30, 2026
-
Planned saleNov 2, 2026Cowan Elvia (Officer) gave notice of a planned sale of 3,000 shares worth about $186K Form 144, approximate sale date Nov 2, 2026, under a 10b5-1 plan adopted Dec 8, 2025
About the company
Vaxcyte, Inc., San Carlos, CA · from the 10-K filed Feb 24, 2026
We are a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. We are re-engineering the way highly complex vaccines are made through the XpressCF™ cell-free protein synthesis platform. Unlike conventional cell-based approaches, our system for producing difficult-to-make proteins and antigens is intended to develop and deliver high-fidelity vaccines with enhanced immunological benefits that are beyond the capabilities of conventional approaches.
- Headquarters
- San Carlos, CA
- Country
- United States
- Reports in
- USD
- Listed on
- Nasdaq
- Fiscal year ends
- December 31
- Last results
- Nov 4, 2026
- Incorporated in
- DE
Email alerts
Sources
The 10-K filed Feb 24, 2026 (open at SEC), compared with the 10-K filed Feb 25, 2025. Numbers from the XBRL of the 10-Ks; filings from SEC EDGAR.
Work with it: Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/PCVX/export.csv") into a cell.